1Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications[J]. Am J Kidney Dis, 2009, 53(Suppl 3): s4-s16.
2Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice[J]. Curt Drug Metab, 2011, 12(1): 57-69.
3lnzucchi SE, Bergenstal RM, Buse JB, et al. Management ofhyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J]. Diabetes Care, 2012, 35(6): 1364-1379.
4Danne T, Bolinder J. New insulins and insulin therapy[J]. Int J Clin Pratt, 2011, 170(Suppl): 26-30.
5Kruger DF, Boucher JL, Banerji MA. Utilizing current diagnostic criteria and treatment algorithms for managing type 2 diabetes mellitus[J]. Postgrad Med, 2011,123(4): 54-62.
6Hung AM, Roumie CL, Greevy RA, et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function[J]. Kidney Int, 2012, 81(7): 698-706.
7gachin JM, Viberti G, Zinman B, et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy[J]. Clin J Am Soc Nephrol, 2011,6(5): 1032-1040.
8Reilly JB, Berns JS. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease[J]. Semin Dial, 2010, 23(2): 163-168.
9Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD[J]. Am J Kidney Dis, 2007, 50(5): 865-879.
10van Berlo-van de Laar IR, Vermeij CG, Doorenbos CJ. Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements[J]. J Clin Pharm Ther, 2011, 36(3): 376-382.
